Recevez les dernières nouvelles sur l'action AIM ImmunoTech avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de AIM

Dernières nouvelles pour

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Inc

Aimfinity Investment Corp I Units (1 Ord Class A , 1 Class 1 War & 1/2 Class 2 War

Aimfinity Investment Corp I Warrants - Class 1 (21/04/2027)

Aimfinity Investment Corp I Unit (1CL A & 1/2 WT CL 2)

Altra Industrial Motion Corp Com

Ainos Inc

Aimia Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

AIMFINITY INV CP I SUBUNT by Aimfinity Investment Corp. I

Aimfinity Investment Corp I

AIMFINITY INV CORP I UTS by Aimfinity Investment Corp. I

Events

Press Releases

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

News

IPOs

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

Health Care

General

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Earnings

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Management

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

OTLK

PALI

SNTI

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aditxt

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptevo Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

enGene Holdings

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Palisade Bio

Polyrizon

PharmaCyte Biotech

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Comments

AIM ImmunoTech Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL